Hepatitis C Therapy in Renal Patients: Who, How, When? - Sorbonne Université Access content directly
Journal Articles Infectious Diseases and Therapy Year : 2016

Hepatitis C Therapy in Renal Patients: Who, How, When?


Renal patients are overexposed to hepatitis C virus (HCV) infection. Hepatitis C virus infection may induce renal disease, i.e., cryoglobulinemic membrano-proliferative glomerulopathy and non-cryoglobulinemic nephropathy. Hepatitis C virus impacts general outcomes in chronic kidney disease, dialysis or transplanted patients. Hepatitis C virus infection is now about to be only part of their medical history thanks to new direct acting antiviral drugs exhibiting as much as over 95% of sustained virological response. All HCV-infected patients potentially can receive the treatment. Control of the virus is associated with better outcomes in all cases, whatever the severity of the hepatic or renal disease. This article focuses on HCV-induced renal diseases, the reciprocal impact of HCV infection on the renal outcome and renal status in liver disease, use of new direct-acting antiviral drugs with dosage adaptations and the most recent safety data.
Fichier principal
Vignette du fichier
art_10.1007_s40121-016-0116-z.pdf (401.78 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-01347092 , version 1 (20-07-2016)


Attribution - NonCommercial



Corinne Isnard Bagnis, Patrice Cacoub. Hepatitis C Therapy in Renal Patients: Who, How, When?. Infectious Diseases and Therapy, 2016, 5 (3), pp.313-327. ⟨10.1007/s40121-016-0116-z⟩. ⟨hal-01347092⟩
70 View
150 Download



Gmail Facebook X LinkedIn More